泊沙康唑预防侵袭性真菌感染有效性和安全性Meta分析  

Efficacy and Safety of Posaconazole for the Prevention of Invasive Fungal Infections: A Meta-Analysis

作　　者：李斐[1] 陈悦涵 李德东[1] LI Fei;CHEN Yuehan;LI Dedong(Chinese PLA General Hospital,Beijing,China 100853)

机构地区：[1]中国人民解放军总医院

出　　处：《中国药业》2019年第14期40-43,共4页China Pharmaceuticals

基　　金：国家自然科学基金[81501730]

摘　　要：目的系统评价泊沙康唑预防侵袭性真菌感染的有效性与安全性。方法计算机检索PubMed,Embase,Cochrane Library数据库自建库至2018年6月的泊沙康唑预防侵袭性真菌感染的随机对照试验,采用RevMan5.0软件进行系统评价。结果共纳入4项研究。Meta分析结果显示,与氟康唑[OR=0.43,95%CI(0.28,0.66),P=0.0001],伊曲康唑[OR=0.74,95%CI(0.23,2.35),P=0.61]或两性霉素B脂质体[OR=0.17,95%CI(0.01,3.69),P=0.26]相比,泊沙康唑预防侵袭性真菌感染效果更好,体现为更低的侵袭性真菌感染发病率、死亡率;泊沙康唑与唑类药物[OR=0.91,95%CI(0.73,1.13),P=0.37]或两性霉素B脂质体[OR=0.54,95%CI(0.13,2.18),P=0.39]不良反应发生率相似。结论与其他抗真菌药物相比,泊沙康唑预防侵袭性真菌感染的有效性及安全性较好。Objective To systematically evaluate the efficacy and safety of posaconazole for the prevention of invasive fungal infections.Methods The randomized controlled trials about posaconazole for the prevention of invasive fungal infection were searched from PubMed,Embase and Cochrane Library since the inception to June 2018.The Meta-analysis was performed by RevMan 5.0 software.Results A total of 4 randomized controlled trials were included in the study.Meta-analysis results showed that posaconazole was more effective in preventing invasive fungal infections than fluconazole[OR=0.43,95%CI(0.28,0.66),P=0.000 1],itraconazole[OR=0.74,95%CI(0.23,2.35),P=0.61]or amphotericin B liposomes[OR=0.17,95%CI(0.01,3.69),P=0.26],which reflected lower incidence of invasive fungal infections and lower mortality.The incidence of adverse reactions of posaconazole was similar to that of azoles[OR=0.91,95%CI(0.73,1.13),P=0.37]or amphotericin B liposomes[OR=0.54,95%CI(0.13,2.18),P=0.39].Conclusion Compared with other antifungal agents,posaconazole is more effective and safe in the prevention of invasive fungal infections.

关 键 词：泊沙康唑 侵袭性真菌感染 有效性 安全性 META分析 系统评价 

分 类 号：R969.4[医药卫生—药理学] R978.5[医药卫生—药学]